etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin + rituximab + nivolumab

This is a multi-agent combination regimen consisting of six chemotherapeutic and immunotherapeutic agents—etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab—and the immune checkpoint inhibitor nivolumab. The combination brings together several mechanisms of action: - Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks. - Prednisone is a synthetic glucocorticoid with anti-inflammatory and lympholytic effects. - Vincristine disrupts microtubule formation during mitosis. - Cyclophosphamide is an alkylating agent causing DNA crosslinking and cell death. - Doxorubicin intercalates into DNA and inhibits topoisomerase II. - Rituximab is a monoclonal antibody targeting CD20 on B cells, leading to cell lysis via immune-mediated mechanisms. - Nivolumab is an immune checkpoint inhibitor targeting PD-1 on T cells to enhance antitumor immunity. This type of regimen would be considered for aggressive B-cell lymphomas or other hematologic malignancies where both cytotoxic chemotherapy and immunotherapy are indicated. While combinations such as R-EPOCH (rituximab plus etoposide, prednisone, vincristine [Oncovin], cyclophosphamide, doxorubicin) are standard in lymphoma treatment protocols, the addition of nivolumab represents an investigational approach aiming to further boost antitumor immunity by blocking PD-1[3][4][5]. Clinical trials have explored similar regimens in diseases like primary mediastinal B-cell lymphoma (PMBCL) and follicular lymphoma[3][4].